CeVi Collection, a Unique Human Viable Cell Collection from Lymphomas to Foster Innovative Lymphoma Diagnostics Tools and Treatments

A unique cryopreserved human viable cell collection

- Biological materials from lymphomas and reactive lymphoid tissues
  - Tumor, blood, bone marrow
  - Cryopreserved in DMSO
  - Derived nucleic acids: DNA/RNA
  - Plasma

Enriched collection

- Perfectly annotated material with biological and clinical data
- State-of-art histopathological diagnosis including IHC results
- Immunophenotyping with a dedicated flow cytometry panel

Biological samples with high quality standards

- ISO 9001 certification of the "Coordination of lymphoma viable cell collection - CeVi"

A wide variety of banked pathologies

Banked pathologies are multiple and represent all subtypes of lymphoma from the most common to the rarest.

A resource for the development of cognitive projects

- In vitro and in vivo experiments
  - ADCP and ADCC analyses on complex cultures from FL and DLBCL
  - Characterization of tumor infiltrating lymphocytes in various lymphomas by flow cytometry, conventional immunohistochemistry techniques

Distribution of samples by organ type

- NT 16%
- Other 2%
- DLBCL 12%
- FL 10%
- Hodgkin 11%
- MCL 7%
- LNH 15%
- Other 9%

Distribution of samples by lymphoma type

- Characterization at the cell level of the cellular diversity of the microenvironment
  - Single-cell approaches at the RNA level and CyTOF to assess the impact of immune microenvironment on the heterogeneity of different types of lymphomas

- Validation of potential biomarkers, drug targets...
  - Study of new biomarkers in Hodgkin lymphoma pathogenesis

- Development of cell culture models

- Ad-hoc collections: prospective collections can be established for specific research projects...

A collaborative project of the CALYM Carnot Institute

- CALYM is an academic research consortium devoted to R&D of solutions for the treatment and diagnosis of lymphoma. Its partnership offers spans from new biological target identification to international Phase III clinical trials and beyond
- CeVi relies on the network of six standardized CALYM research laboratories, backed by local biobanks, to develop "CeVi platforms"

A resource of valuable biological material for industry

- An open resource for CALYM researchers to establish R&D partnerships with industry
- Companies can access the collection through a contract R&D project with one or more teams of the CALYM consortium

contact@calym.org

© sola_sola - Fotolia, Institut Carnot CALYM - 2017